Cisplatin eligibility in the neoadjuvant setting of patients with muscle-invasive bladder cancer undergoing radical cystectomy
Renate Pichler(Innsbruck Medical University), Laura S. Mertens(Oncode Institute), Tobias Klatte(Helios Hospital Bad Saarow), Eugenio Bologna(Policlinico Umberto I), Josef Fritz(Innsbruck Medical University), Keiichiro Mori(Jikei University School of Medicine), Barbara Erber(Charité - Universitätsmedizin Berlin), Anna Cadenar(University of Florence), Gautier Marcq(Centre National de la Recherche Scientifique), Peter A. Seeber(Innsbruck Medical University), Maria De Santis(Medical University of Vienna), Markus von Deimling(Universität Hamburg), Marco Moschini(Vita-Salute San Raffaele University), Benjamin Pradere(Hôpital de la Croix-Rousse), Costantino Leonardo(Policlinico Umberto I), Rana Tahbaz(Charité - Universitätsmedizin Berlin), Andrea Mari(Azienda Ospedaliero-Universitaria Careggi), Francesco Del Giudice(Sapienza University of Rome), Andreas Kronbichler(Innsbruck Medical University), Margit Fisch(Universität Hamburg), Felizian Lackner(Innsbruck Medical University)
Cited by 9
Related Papers
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|618
2-<sup>18</sup>fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial
|Journal of Clinical Oncology|2004|423
Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2011|249